Eylea

Eylea
Name	Eylea
Caption	Aflibercept (Eylea) injection vial
Tradename	Eylea
Generic	Aflibercept
Routes of administration	Intravitreal injection
Class	Anti-VEGF therapy

Eylea is a recombinant fusion protein used as an intravitreal treatment for retinal vascular disorders that threaten sight, developed and marketed by a multinational pharmaceutical company. Its indications include neovascular retinal conditions and diabetic retinal disease, and it is administered by ophthalmologists in clinic settings following standards established by professional societies. Clinical development involved major clinical trial networks and regulatory agencies across North America, Europe, and Asia.

Medical uses

Eylea is indicated for treatment of neovascular ocular conditions such as wet Age-related macular degeneration, macular edema secondary to Central retinal vein occlusion, macular edema secondary to Branch retinal vein occlusion, and diabetic macular edema in patients with diabetic eye disease such as proliferative changes associated with Diabetic retinopathy. It is also used for vision-threatening complications encountered in patients with ischemic retinal disorders managed by retinal specialists at academic centers like Moorfields Eye Hospital, Bascom Palmer Eye Institute, and university hospitals in networks collaborating with organizations such as the American Academy of Ophthalmology and the European Society of Retina Specialists. Off-label use and extension to other retinal vascular pathologies have been evaluated in investigator-initiated studies at institutions including Massachusetts General Hospital, Johns Hopkins Hospital, and University College London Hospital.

Mechanism of action

Aflibercept acts as a soluble decoy receptor that binds vascular endothelial growth factors including Vascular endothelial growth factor A, Vascular endothelial growth factor B, and placental growth factor, thereby inhibiting ligand-driven signaling through receptors such as VEGFR-1 and VEGFR-2 on retinal endothelial cells. By neutralizing these factors, it reduces pathologic angiogenesis and vascular permeability implicated in neovascularization described in classic studies from groups affiliated with National Eye Institute investigators and laboratory models developed at institutions like Scripps Research and Cold Spring Harbor Laboratory. Its biochemical design draws on molecular engineering advances reported by academic groups collaborating with biotech firms and influenced by prior therapies such as Ranibizumab and Bevacizumab.

Dosage and administration

Eylea is supplied for intravitreal injection by licensed ophthalmologists and retina specialists following procedural protocols endorsed by bodies like the American Society of Retina Specialists, with aseptic technique comparable to practices at tertiary centers such as Wills Eye Hospital. Typical regimens for neovascular conditions start with monthly dosing for a loading phase followed by dosing every 8 weeks, while adjustments for diabetic macular edema or retinal vein occlusion may follow alternative schedules determined in trials coordinated by organizations like the Diabetic Retinopathy Clinical Research Network. Administration requires informed consent and monitoring schedules that mirror guidance from regulatory agencies including the Food and Drug Administration and the European Medicines Agency regarding intraocular pressure checks and infection surveillance.

Efficacy and clinical trials

Efficacy was established in pivotal randomized controlled trials comparing aflibercept with sham or active comparators, conducted across multicenter networks including academic sites affiliated with University of California, Los Angeles, University of Pennsylvania, King's College London, and trial sponsors collaborating with groups such as the National Institutes of Health. Key endpoints included improvements in best-corrected visual acuity and reduction in central retinal thickness assessed by optical coherence tomography devices from manufacturers like Zeiss, with statistical analyses consistent with standards used in trials for Ranibizumab and other anti-VEGF agents. Long-term extension studies and real-world evidence collected via registries associated with professional societies such as the European Society of Retina Specialists and registries run by hospitals like Tufts Medical Center contributed to comparative effectiveness data and health technology assessments performed by agencies including the National Institute for Health and Care Excellence.

Adverse effects and safety

Safety profiles reported in trials and pharmacovigilance databases overseen by the Food and Drug Administration and European Medicines Agency include procedure-related risks such as endophthalmitis, intraocular inflammation, retinal detachment, and elevated intraocular pressure, along with systemic events that have been monitored due to theoretical thromboembolic risk noted in postmarketing surveillance by organizations like the World Health Organization and national pharmacovigilance centers. Risk mitigation strategies reflect guidelines from specialty societies including the American Academy of Ophthalmology and institution-specific protocols at centers like Cleveland Clinic to reduce infection and manage adverse ocular events. Pregnancy considerations and immunogenicity assessments were included in regulatory submissions reviewed by panels at agencies such as the Food and Drug Administration and advisory committees convened at the European Medicines Agency.

Chemistry and formulation

Aflibercept is a recombinant fusion protein composed of extracellular domains of human VEGFR-1 and VEGFR-2 fused to the Fc portion of human immunoglobulin G1, produced in mammalian cell culture systems using biotechnology processes similar to those employed for biologics developed by companies collaborating with contract manufacturing organizations and bioprocessing facilities. Its formulation for intravitreal use contains buffers and stabilizers optimized for ocular tolerability and shelf-life, with packaging and sterility standards aligned with pharmacopoeial guidance and good manufacturing practice inspections conducted by regulators such as the Food and Drug Administration and national authorities in jurisdictions including Japan and Australia.

Regulatory history and market information

Eylea received regulatory approval following submission of pivotal data to agencies including the Food and Drug Administration and the European Medicines Agency, with subsequent approvals in countries administered by regulators like Health Canada and the Pharmaceuticals and Medical Devices Agency. Its development involved partnerships between biotechnology firms and multinational pharmaceutical companies, commercialization strategies that included negotiations with national health systems and payers such as NHS England, and market access activities assessed by health technology assessment bodies like the National Institute for Health and Care Excellence. Postmarketing surveillance and patent litigation have been matters in legal and policy arenas involving stakeholders such as generic and biosimilar developers, with ongoing evaluations of biosimilar pathways in regions including the European Union and the United States.

Category:Ophthalmic drugs